الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

نشره PR Newswire · الولايات المتحدة منذ 2 س

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89;…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Business Wire

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Associated Press (Business)

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

مشاركة

يستحق القراءة أيضًا

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

Brazil’s Lula opens state toolbox to woo voters in runoff against Bolsonaro. Here’s what is on offer

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows